Alkermes shares slid -9.6% this afternoon. Here's what you need to know about the mid-capPharmaceutical company:
-
Alkermes has logged a 10.0% 52 week change, compared to 12.0% for the S&P 500
-
ALKS has an average analyst rating of buy and is -31.75% away from its mean target price of $35.8 per share
-
Its trailing earnings per share (EPS) is $0.57, which brings its trailing Price to Earnings (P/E) ratio to 42.9. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $1.94 and its forward P/E ratio is 12.6
-
The company has a Price to Book (P/B) ratio of 3.18 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 2.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $59.3 Million and the average free cash flow growth rate is 0.0%
-
Alkermes's revenues have an average growth rate of 0.0% with operating expenses growing at -22.4%. The company's current operating margins stand at -12.8%